Trials / Recruiting
RecruitingNCT07227415
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 224 (estimated)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer. Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.
Conditions
- Carcinoma, Renal Cell
- Advanced Renal Cell Carcinoma
- Renal Cancer
- Renal Neoplasm
- Clear Cell Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Clear-cell Metastatic Renal Cell Carcinoma
- Carcinoma, Renal Cell Metastasis
- Advanced or Metastatic Renal Cell Carcinoma
- Carcinoma, Renal Cell, Advanced
- Metastatic Renal Cell Cancer
- Metastatic Renal Cell Carcinoma ( mRCC)
- Metastatic/Advanced Renal Cell Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PF-08634404 | Concentrate for solution for infusion |
| DRUG | Combination 1 | Combination Drug 1 |
| DRUG | Combination 2 | Combination Drug 2 |
Timeline
- Start date
- 2026-03-12
- Primary completion
- 2027-11-02
- Completion
- 2028-11-01
- First posted
- 2025-11-12
- Last updated
- 2026-04-07
Locations
47 sites across 3 countries: United States, Australia, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07227415. Inclusion in this directory is not an endorsement.